{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T09:56:02Z","timestamp":1766138162353,"version":"3.40.4"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10072-022-06568-w","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T06:02:33Z","timestamp":1672207353000},"page":"1419-1422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3131-032X","authenticated-orcid":false,"given":"Daniele","family":"Severi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniello","family":"Iovino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Nolano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiore","family":"Manganelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Tozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"6568_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-02004889-2","author":"F Manganelli","year":"2020","unstructured":"Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D (2020) Hereditary transthyretin amyloidosis overview. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-02004889-2. (Epub ahead of print. PMID: 33188616)","journal-title":"Neurol Sci"},{"issue":"2","key":"6568_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/jns.12451","volume":"26","author":"S Tozza","year":"2021","unstructured":"Tozza S, Severi D, Spina E, Iovino A, Aruta F, Ruggiero L, Dubbioso R, Iodice R, Nolano M, Manganelli F (2021) The neuropathy in hereditary transthyretin amyloidosis: a narrative review. J Peripher Nerv Syst. 26(2):155\u2013159. https:\/\/doi.org\/10.1111\/jns.12451. (Epub 2021 May 11. PMID: 33960565; PMCID: PMC8360044)","journal-title":"J Peripher Nerv Syst."},{"issue":"5","key":"6568_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/brainsci11050545.PMID:33925301;PMCID:PMC8146901","volume":"11","author":"M Russo","year":"2021","unstructured":"Russo M, Gentile L, Di Stefano V, Di Bella G, Minutoli F, Toscano A, Brighina F, Vita G, Mazzeo A (2021Apr 27) Use of drugs for ATTRv amyloidosis in the real world: how therapy is changing survival in a non-endemic area. Brain Sci 11(5):545. https:\/\/doi.org\/10.3390\/brainsci11050545.PMID:33925301;PMCID:PMC8146901","journal-title":"Brain Sci"},{"issue":"1","key":"6568_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plant\u00e9Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Concei\u00e7\u00e3o I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018Jul 5) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793. (PMID: 29972757)","journal-title":"N Engl J Med"},{"issue":"8","key":"6568_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/17512433.2019.1635008","volume":"12","author":"MA Gertz","year":"2019","unstructured":"Gertz MA, Scheinberg M, Waddington-Cruz M, Heitner SB, Karam C, Drachman B, Khella S, Whelan C, Obici L (2019Aug) Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Expert Rev Clin Pharmacol 12(8):701\u2013711. https:\/\/doi.org\/10.1080\/17512433.2019.1635008. (Epub 2019 Jul 3 PMID: 31268366)","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"6568_CR6","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1111\/ene.15325","volume":"29","author":"M Luigetti","year":"2022","unstructured":"Luigetti M, Antonini G, Di Paolantonio A, Gentile L, Grandis M, Leonardi L, Lozza A, Manganelli F, Mazzeo A, Mussinelli R, My F, Obici L, Maria Pennisi E, Romozzi M, Russo M, Sabatelli M, Salvalaggio A, Tagliapietra M, Tozza S (2022) Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: data from an early-access program in Italy. Eur J Neurol 29(7):2148\u20132155. https:\/\/doi.org\/10.1111\/ene.15325. (Epub 2022 Mar 28. PMID: 35289020; PMCID: PMC9314115)","journal-title":"Eur J Neurol"},{"issue":"13","key":"6568_CR7","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2147\/DDDT.S162913","volume":"6","author":"V Mathew","year":"2019","unstructured":"Mathew V, Wang AK (2019May) Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis. Drug Des Devel Ther 6(13):1515\u20131525. https:\/\/doi.org\/10.2147\/DDDT.S162913. (PMID:31118583;PMCID:PMC6507904)","journal-title":"Drug Des Devel Ther"},{"issue":"15","key":"6568_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2147\/PGPM.S359851","volume":"12","author":"V Di Stefano","year":"2022","unstructured":"Di Stefano V, Fava A, Gentile L, Guaraldi P, Leonardi L, Poli L, Tagliapietra M, Vastola M, Fanara S, Ferrero B, Giorgi M, Perfetto F, Russo M, Russo D (2022May) Italian real-life experience of patients with hereditary transthyretin amyloidosis treated with patisiran. Pharmgenomics Pers Med 12(15):499\u2013514. https:\/\/doi.org\/10.2147\/PGPM.S359851. (PMID:35592550;PMCID:PMC9113125)","journal-title":"Pharmgenomics Pers Med"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06568-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:28:03Z","timestamp":1744208883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06568-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["6568"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06568-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2022,12,28]]},"assertion":[{"value":"13 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived by the local Ethics Committee in view of the retrospective nature of\u00a0the study and all the procedures being performed were part of the routine\u00a0care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval\u00a0"}},{"value":"Informed consent Informed consent for publication was collected from patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"D.S. has received a travel grant to attend scientific meetings from SOBI. F.M. received personal fees for scientific events from Alfa-Sigma, Alnylam Pharmaceuticals, and Akcea Therapeutics, and has received a travel grant to attend scientific meetings from CSL Behring. S.T. received personal fees for scientific events from Alnyalm Pharmaceuticals and Amicus Therapeutics, and travel grants to attend scientific meetings from Akcea Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}